1. Home
  2. TARS vs CHRN Comparison

TARS vs CHRN Comparison

Compare TARS & CHRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tarsus Pharmaceuticals Inc.

TARS

Tarsus Pharmaceuticals Inc.

SELL

Current Price

$69.88

Market Cap

3.6B

Sector

Health Care

ML Signal

SELL

Logo ChronoScale Corporation Common Stock

CHRN

ChronoScale Corporation Common Stock

HOLD

Current Price

$16.14

Market Cap

2.9B

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
TARS
CHRN
Founded
2016
2026
Country
United States
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Industrial Machinery/Components
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
3.6B
2.9B
IPO Year
2020
2012

Fundamental Metrics

Financial Performance
Metric
TARS
CHRN
Price
$69.88
$16.14
Analyst Decision
Strong Buy
Analyst Count
10
0
Target Price
★ $99.80
N/A
AVG Volume (30 Days)
★ 589.3K
120.6K
Earning Date
11-03-2026
10-14-2026
Dividend Yield
N/A
N/A
EPS Growth
48.21
★ 92.67
EPS
N/A
★ N/A
Revenue
★ $451,360,000.00
N/A
Revenue This Year
$61.17
$84.77
Revenue Next Year
$26.47
$603.10
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 146.71
N/A
52 Week Low
$53.89
$12.62
52 Week High
$91.53
$30.00

Technical Indicators

Market Signals
Indicator
TARS
CHRN
Relative Strength Index (RSI) 39.09 35.37
Support Level $69.47 N/A
Resistance Level $73.45 $22.29
Average True Range (ATR) 2.85 1.53
MACD -0.68 -0.41
Stochastic Oscillator 0.91 35.08

Price Performance

Historical Comparison
TARS
CHRN

About TARS Tarsus Pharmaceuticals Inc.

Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.

About CHRN ChronoScale Corporation Common Stock

ChronoScale Holdings Corp is providing cloud services to customers at third-party colocation centers located in Colorado, Minnesota and Utah, such as artificial intelligence and machine learning developers, seeking to develop their products. It design, develop, and market exoskeleton and complementary products that augment human strength, endurance, and mobility. Its Cloud Business provides graphics processing unit (GPU) computing solutions that enable customers to execute critical workloads related to artificial intelligence (AI), machine learning (ML), rendering, and other High Performance Computing (HPC) tasks at scale in a capacity-constrained market. It has one operating segment Cloud Business.

Share on Social Networks: